gcc-4401
Small moleculeexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2012 (NCT01651234)
Timeline
2010s
- Jan 1, 2012
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Coagulation factor XINHIBITOR
F10 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- gcc-4401
- gcc-4401c
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01954238 | Phase 1 | Aug 1, 2013 | California Clinical Trials, Green Cross Corporation, Parexel |
| NCT01651234 | Phase 1 | Mar 1, 2012 | Green Cross Corporation, IQVIA |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Green Cross Corporation | For profit | 2 | 2 | 1 | 2012 |
| California Clinical Trials | For profit | 1 | 0 | 1 | 2013 |
| IQVIA | For profit | 1 | 0 | 1 | 2012 |
| Parexel | For profit | 1 | 0 | 1 | 2013 |
4 organizations
Page 1 / 1